The information on this website is not intended for diagnosis or treatment. Please consult your physician for health concerns.

Skip to main content

Ga-68 PSMA PET-CT (Prostate Cancer)

Molecular imaging targeting prostate-specific membrane antigen for staging and recurrence detection.

Written by: Saygı Hospital Health Guide Editorial Board
Last updated:

This content has been compiled by the Saygı Hospital Health Guide Editorial Board and is periodically reviewed by a specialist physician.

References (5)

This content is for informational purposes only and does not constitute medical advice. You can book an appointment at our Radyoloji department. Book Appointment →

What is Ga-68 PSMA PET-CT (Prostate Cancer)?

Ga-68 PSMA PET-CT uses gallium-68 labeled small molecules (PSMA-11, PSMA-617) that bind prostate-specific membrane antigen, which is overexpressed in most prostate adenocarcinomas.

Indications include initial staging in unfavorable intermediate to high-risk disease, evaluation of biochemical recurrence after definitive therapy, and selection for PSMA-directed radioligand therapy (Lu-177 PSMA).

Reporting follows PROMISE/E-PSMA frameworks. Sensitivity exceeds conventional imaging at PSA <2 ng/mL after radical prostatectomy or radiotherapy.

Symptoms

Newly diagnosed unfavorable intermediate or high-risk prostate cancer
Rising PSA after radical prostatectomy
Rising PSA after definitive radiotherapy
Evaluation of metastatic burden before therapy change
Selection for Lu-177 PSMA radioligand therapy
Suspicious bone scan or CT findings to confirm

Risk Factors

Renal impairment (relative — adjust for clearance)
Recent intense androgen deprivation may alter uptake
Other PSMA-expressing tumors (rare false positives)
Inflammatory and benign uptake patterns
Patient must lie still for ~20–30 minutes

When to See a Doctor?

If you experience any of the following symptoms, seek medical attention promptly:

  • PSA persistence or rise after surgery/radiation
  • Equivocal bone scan/CT in known prostate cancer
  • High-risk disease at diagnosis
  • Need to plan salvage radiotherapy or systemic therapy
  • Eligibility evaluation for Lu-177 PSMA therapy

Treatment Methods

01
PROMISE/E-PSMA structured reporting
02
Combine with diagnostic CT and MRI when needed
03
Tumor board discussion for management implications
04
Hydration and bladder voiding before imaging
05
Quality control of imaging protocol and dosimetry
06
Multidisciplinary referral for theranostics when indicated

Which Department to Visit?

You can visit our Radyoloji department for these complaints. Our specialist physicians will create the most suitable treatment plan for you.

Learn About Radyoloji Department

Let us help you

You can make an appointment with our specialists or contact us for your concerns.

Health Disclaimer: The information on this page is prepared for general informational purposes only. It does not replace medical diagnosis and treatment. Please consult your physician for your complaints. Saygı Hospital does not accept responsibility for actions taken based on the information on this page.